Biopharmaceutical company PlasmaGen Biosciences has raised ₹150 crore in a fresh funding round led by ViNS Bioproducts, with participation from high-net-worth individuals (HNIs), family offices, pharmaceutical entrepreneurs, and existing investors, the company said.
The latest fundraise values the Bengaluru-based company at over ₹1,500 crore and takes its total capital raised to more than ₹600 crore till date. PlasmaGen is backed by marquee investors including Eight Roads Ventures, F-Prime Capital, Fidelity’s FIL Capital Investments, UK-based Artian Investments, along with several prominent individual investors.
Founded in 2010, PlasmaGen develops, manufactures and markets blood plasma-derived therapies, including albumin, immunoglobulins, anti-D products and clotting factors. These critical therapies are widely used across neurology, hematology and critical care, and are supplied to both private hospitals and state government healthcare systems across India.
The funding comes close on the heels of PlasmaGen commencing commercial operations in December 2023 at its plasma fractionation facility in Kolar, near Bengaluru, marking a key milestone in the company’s scale-up journey.
ViNS Bioproducts, the lead investor in the round, is a 28-year-old pharmaceutical company best known for developing and manufacturing antivenoms for snake and scorpion bites, along with antitoxins for tetanus, diphtheria and gangrene, and anti-rabies serums.
PlasmaGen said the newly raised capital will be used to expand international operations, broaden its product portfolio, and strengthen manufacturing capacity and leadership capabilities as it targets accelerated growth in both domestic and overseas markets.
“The past year has been transformational for PlasmaGen, marking a significant step change in our scale and reach,” said Vivek V Kamath, CEO of PlasmaGen Biosciences. “This momentum has placed the company on an exponential growth trajectory, and the fresh capital will help us build a globally competitive plasma therapeutics platform.”
With rising demand for plasma-derived therapies and increasing focus on healthcare self reliance, PlasmaGen is positioning itself as a key player in India’s evolving biopharma ecosystem.
Follow Startupbydoc for daily startup insights, funding news, IPO analysis, and business breakdowns.